The ALPMF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALPMF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ALPMF Detailed Price Forecast - CNN Money||View ALPMF Detailed Summary - Google Finance|
|View ALPMF Detailed Summary - Yahoo! Finance||View ALPMF Stock Research & Analysis - Zacks.com|
|View ALPMF Trends & Analysis - Trade-Ideas||View ALPMF Major Holders - Barrons|
|View ALPMF Call Transcripts - NASDAQ||View ALPMF Breaking News & Analysis - Seeking Alpha|
|View ALPMF Annual Report - CompanySpotlight.com||View ALPMF OTC Short Report - OTCShortReport.com|
|View ALPMF Fundamentals - TradeKing||View ALPMF SEC Filings - Bar Chart|
|View Historical Prices for ALPMF - The WSJ||View Performance/Total Return for ALPMF - Morningstar|
|View the Analyst Estimates for ALPMF - MarketWatch||View the Earnings History for ALPMF - CNBC|
|View the ALPMF Earnings - StockMarketWatch||View ALPMF Buy or Sell Recommendations - MacroAxis|
|View the ALPMF Bullish Patterns - American Bulls||View ALPMF Short Pain Metrics - ShortPainBot.com|
|View ALPMF Stock Mentions - StockTwits||View ALPMF Stock Mentions - PennyStockTweets|
|View ALPMF Stock Mentions - Twitter||View ALPMF Investment Forum News - Investor Hub|
|View ALPMF Stock Mentions - Yahoo! Message Board||View ALPMF Stock Mentions - Seeking Alpha|
|View Insider Transactions for ALPMF - SECform4.com||View Insider Transactions for ALPMF - Insider Cow|
|View ALPMF Major Holdings Summary - CNBC||View Insider Disclosure for ALPMF - OTC Markets|
|View Insider Transactions for ALPMF - Yahoo! Finance||View Institutional Holdings for ALPMF - NASDAQ|
|View ALPMF Stock Insight & Charts - FinViz.com||View ALPMF Investment Charts - StockCharts.com|
|View ALPMF Stock Overview & Charts - BarChart||View ALPMF User Generated Charts - Trading View|
Pfizer, Astellas revise two cancer drug trial protocols to speed up results
Posted on Wednesday August 22, 2018
The companies now expect the ARCHES trial to end late this year, ahead of the previously anticipated completion date of April 2020, and the EMBARK trial to complete by mid-2020, earlier than the prior goal of March 2021. Both trials are testing Xtandi in men with hormone-sensitive prostate cancer. Xtandi is already approved in the United States to treat castration-resistant prostate cancer and brought Pfizer revenue of $171 million in the latest reported quarter.
[$$] Astellas Pharma Buys U.K.'s Quethera
Posted on Friday August 10, 2018
Astellas Pharma Inc. said Friday it acquired Quethera Ltd., a U.K. company focused on developing treatments for ocular disorders such as glaucoma.
Astellas Is Considering Selling Europe Assets to Raise Cash
Posted on Wednesday July 18, 2018
Astellas Pharma Inc. is considering a sale of some central and eastern European assets as the Japanese drugmaker seeks to trim its portfolio and raise cash, according to people familiar with the matter. Astellas is working with Jefferies Financial Group Inc. on the potential disposal, which includes Russian assets and has drawn interest from private equity firms and other pharmaceutical companies, the people said, asking not to be identified because the deliberations are private. The portfolio under review includes drugs to prevent infections and pain treatments, the people said.
Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
Posted on Monday July 16, 2018
FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.